Market Research

Medical technology breakthroughs have led to a radical transformation in patient care by enabling a greater focus on clinical outcomes. For more, visit: https://www.marketsandmarkets.com

Veterinary Care Market worth USD 9 billion : Analysis of Worldwide Industry Trends and Opportunities

The veterinary care market is expected to foresee positive trends throughout the forecast period. Substantial market growth can be attributed to the rising initiatives undertaken by the regulatory authorities. Government authorities collaborate with veterinarians and develop schemes that assure the availability of optimum inventory at fields for treating the farm animals.

Latin America animal health market size is projected to reach around USD 9 billion by 2025 from around USD 5.2 billion in 2018, at a CAGR of 7.3% during the forecast period.

This study involved the extensive use of both primary and secondary sources. The research process included a study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Recent Developments

  • In February 2020, Zoetis acquired Ethos Diagnostic Science. This acquisition will not only expand company’s product portfolio but will also help the company to grow exponentially in the veterinary space.
  • In November 2019, Zoetis acquired ZNLabs a reference laboratory company that is operational across the U.S. This has helped the company to enhance its offerings and improve its business performance
  • In June 2020, Merck completed the acquisition of a Quantified Ag leading data analytics company that monitors cattle temperature and helps in the early detection of any disease. This acquisition will diversify Merck’s veterinary product offerings and will positively impact the company’s profitability.

The animal type segment of the veterinary care market is bifurcated further into dogs, cats, pigs, poultry, cattle, and horses. Livestock animals such as cattle and poultry are expected to experience higher medicalization rates during the forecast years. In emerging economies such as the Philippines and Vietnam, earlier, poultry health was neglected, and owners used to discard the chickens in bulk during a virus outbreak.

Download PDF Brochure @   https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=78396315  

Based on the type of treatment, the veterinary care market is segmented into no medicalization, basic medicalization, and under veterinary care. The percentage of non-medicalized animals is going to experience a decline over the next few years. The major reason behind this sharp decrease in no medicalization in animals is rising awareness amongst the farm as well as the pet owners.

The geographical regions mapped in the report are:1. North America2. Europe3. Asia-Pacific4. Africa5. Latin America

Latin America is one of the regions that has experienced significant growth in animal health space for the past few years. Countries such as Brazil and Argentina have shown potential demand for veterinary products and services. Several major players in the veterinary space have considered expansion Latin America due to the enormous growth opportunities it offers in the animal health industry.

Some key players mentioned in the research report are:

The leading players in the animal treatment market include Zoetis (US), Merck (US), Boehringer Ingelheim (Germany), Elanco (US), Ceva (France), Phibro Animal Health Corporation (US), Virbac SA (France), IDEXX Laboratories, Inc., Neogen Corporation (US), Heska Corporation (US) and others. These players undertake several strategic initiatives such as mergers, acquisitions, new product launches, and geographical expansions that helps them in sustaining market competition.

Request for sample pages @  https://www.marketsandmarkets.com/requestsampleNew.asp?id=78396315  

Residential Air Purifiers Market worth USD 13.6 billion by 2025 : Increasing Urbanization & Indoor Air Pollution

The growing awareness among consumers regarding air purification in the wake of COVID-19 is an opportunity for air purifier retailers to scale up their sales. Some companies are increasing the production of air quality systems with the addition of different technologies such as High-Efficiency Particulate Air (NASDAQ:HEPA) filters, photocatalytic purifiers, activated carbon purifiers, and ionic filters.

[131 Pages Report] The residential air purifiers market is projected to reach USD 13.6 billion by 2025 from USD 9.2 billion in 2020, at a CAGR of 8.2% during the forecast period.

Market Dynamics

  • Growing popularity of smart homes
  • Increasing urbanization and indoor air pollution
  • Supportive government regulations for effective air pollution monitoring and control
  • Increasing public awareness pertaining to the healthcare implications of air pollution

COVID-19 Impact on Global Residential Air Purifiers Market

The COVID-19 outbreak has generated major remunerative opportunities for air purifier manufacturers, with high-performance units, comprising HEPA and activated carbon technologies, being highly popular, to minimize the spread of the virus for enclosed spaces. Premium, high-performance air purifiers are capable of filtering out particles up to 1 micron, and the size of the COVID-19 virus is estimated to be around 1.2 microns. Consequently, manufacturers have displayed confidence in being able to provide a solution for indoor environments, during the outbreak, which will sustain demand for the near future.Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=40172748

Based on technology, the residential air purifiers market is segmented into HEPA filters (high-efficiency particulate arrestence or high-efficiency particulate air) and other technologies. The other technologies segment comprises electrostatic precipitators, activated carbon, UV filters, and ionic filters. The HEPA segment accounted for the larger market share in 2019. The growing concern for environmental sustainability, increasing public awareness pertaining to the healthcare implications of air pollution, and the growing popularity of smart homes/ambient-assisted living has resulted in the increased adoption of the HEPA technology in the residential air purifiers market.

The geographical regions mapped in the report are:1. North America2. Europe3. Asia-Pacific4. RoW5. Latin America6. Middle East & Africa

Asia Pacific is the largest regional market for residential air purifiers. The fast adoption of advanced indoor air quality monitoring technologies, ongoing technological advancements in the field of particulate sensors, rising public-private funding and investments, and the presence of supportive government regulations are key factor driving the residential air purifiers market in Asia Pacific.

Request for sample pages @  https://www.marketsandmarkets.com/requestsampleNew.asp?id=40172748 

Some key players mentioned in the research report are:

The top market players in the global residential air purifiers market include Daikin Industries, Ltd. (Japan), Sharp Corporation (Japan), Honeywell International Inc. (US), Samsung Electronics Co., Ltd. (South Korea), LG Electronics Inc. (South Korea), Koninklijke Philips N.V. (Netherlands), Dyson (NASDAQ:UK), Unilever Group (UK), Panasonic Corporation (Japan), Whirlpool Corporation (US), AllerAir Industries Inc. (US), IQAir (Switzerland), WINIX Co., Ltd. (South Korea), Xiaomi Corporation (CHINA), Camfil AB (Sweden), Alen Corporation (US), Airgle Corporation (US), Hunter Pure Air (US), Kent RO Systems Ltd. (India), and HSIL Limited (India).

Source: http://www.marketsandmarkets.com/Market-Reports/residential-air-purifiers-market-40172748.html

Protein A Resin Market Worth USD 1.9 Billion by 2025 Is Expected To Witness Growth In The Coming Years

[140 Pages Report] The protein A resin market is expected to reach USD 1.9 billion by 2025 from USD 1.1 billion in 2020, at a CAGR of 11.4% during the forecast period.

The study involved four major activities in estimating the current size for the protein A resin market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.

Market Dynamics

  • Growing demand for disposable pre-packed columns
  • Increasing demand for therapeutic antibodies
  • Increasing pharmaceutical R&D spending

COVID-19 Impact on the Protein A Resin Market

For the past 30 years, monoclonal antibodies have transformed the way we treat various diseases—they have proven to be more effective, better tolerated, and easier to deliver than other treatments. Researchers are optimistic that monoclonal antibodies could help prevent and treat early infections of COVID-19. Several monoclonal antibodies that are licensed or in development for other diseases are in clinical trials for COVID-19.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=19196962

Chromatography is an essential step in the purification of monoclonal antibodies (mAbs). Over the past decade, there has been a tremendous increase in the demand for monoclonal antibodies in oncology and several other therapeutic areas, including neurological, autoimmune, and inflammatory disorders. As a result, almost all major pharmaceutical companies are focusing on the R&D of therapeutic antibodies.

The geographical regions mapped in the report are:1. North America2. Europe3. Asia-Pacific4. RoW

Geographically, North America is expected to dominate the global the protein A resin market in 2019, while the Asia Pacific region is expected to register the highest CAGR during the forecast period. The high growth in this region can be attributed to the increased R&D activities, as APAC has emerged as a key pharmaceutical and biopharmaceutical research hub. Considering this, a number of key pharmaceutical and biopharmaceutical companies have set up their research centers in the region. Also, local major players such as Ranbaxy, Dr. Reddy’s, Cipla, Lupin, and Cadila are actively involved in research on biosimilars and generic drugs.

Some key players mentioned in the research report are:

GE Healthcare (US), Merck Millipore (Germany), Repligen Corporation (US), Thermo Fisher Scientific (US), Tosoh Bioscience (Japan), Purolite Corporation (US), and Novasep Holding SAS (France), are considered to be the leading players in the protein A resin market.

Request for sample pages https://www.marketsandmarkets.com/requestsampleNew.asp?id=19196962

Source: http://www.marketsandmarkets.com/Market-Reports/protein-a-resin-market-19196962.html

Ambulatory Surgical Centers Market : Analysis of Worldwide Industry Trends and Opportunities

[176 Pages Report] The Ambulatory surgical centers market is projected to reach USD 7.2 billion by 2025 from 2.1 billion in 2020, at a CAGR of 27.6% during the forecast period

The study involved four major activities in estimating the size of the Ambulatory Surgical Centers market. Exhaustive secondary research was done to collect information on the adoption of different technologies and their regional adoption trends. Industry experts further validated the data obtained through secondary research through primary research.

Market Dynamics

  • Increasing number of Ambulatory Surgical Centers
  • Need to curtail escalating healthcare costs
  • Growing use of IT solutions among ASCs
  • Growing demand for cloud-based solutions
  • Shift towards patient-centric healthcare delivery

Based on products and services, the Ambulatory surgical centers market is segmented into clinical solutions, non-clinical solutions, and HCIT outsourcing services. In 2019, the clinical solutions segment accounted for the largest share of the Ambulatory surgical centers market. The need to control the increasing healthcare costs and improve the efficiency of healthcare services by reducing medical errors are a major driver that propels the demand for healthcare provider solutions.

Download PDF Brochure @  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=182183086 

Based on components, the Ambulatory surgical centers market is segmented into services, software, and hardware. The services segment accounted for the largest market share in 2019. This is due to the introduction of complex software, the need for integration and interoperability of software, the growing demand for consulting and outsourcing of various healthcare processes such as revenue cycle management, EHR management, and fraud detection.

The geographical regions mapped in the report are:1. North America2. Europe3. Asia-Pacific4. Latin America5. Middle East & Africa

North America accounted for the largest share of the Ambulatory surgical centers market, followed by Europe. The large share of this region can be attributed to the high adoption of Ambulatory surgical centers for reducing the soaring healthcare costs, increasing volume of surgical procedures performed, and the presence of significant market players, such as Epic Systems Corporation (US), Cerner Corporation (US), McKesson Corporation (US), Philips Healthcare (Netherlands), and Allscripts Healthcare Solutions, Inc. (US).

Some key players mentioned in the research report are:

Cerner Corporation (US), McKesson Corporation (US), Allscripts Healthcare Solutions, Inc. (US), GE Healthcare (US), Philips Healthcare (Netherlands), athenahealth, Inc. (US), Optum (US), Epic Systems Corporation (US), Medical Information Technology, Inc. (MEDITECH) (US), eClinicalWorks (US), athenahealth, Inc. (US), Advanced Data Systems Corporation (US), NextGen Healthcare (US), CureMD (US), HST Pathways (US), and Surgical Information Systems (US).

Request for sample pages @  https://www.marketsandmarkets.com/requestsampleNew.asp?id=182183086 

Source: http://www.marketsandmarkets.com/Market-Reports/ambulatory-surgical-center-market-182183086.html

Solvent Evaporation Market : Increasing Research And Development Expenditure

Major Growth Boosters :

Growth in this market is driven majorly by the growth of the biologics sector, increasing research & development expenditure, rising purity demands in end-use markets, and the growing development of large molecule biopharmaceuticals.

Expected Revenue Growth:

[138 Pages Report] The global solvent evaporation market size is projected to reach USD 694 million by 2024 from USD 487 million in 2019, at a CAGR of 7.3%.

What This Report Will Provide?

In this report, the global market for solvent evaporators was arrived at after the assessment of major product segments and their shares. For this purpose, the share of major product segments was determined through various insights gathered during primary and secondary research.

The research process involved the study of multiple factors affecting the industry to identify segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=68290365

Recent Developments

  • In June 2019, Yamato Scientific relocated its headquarters to Tokyo, Japan.
  • In July 2019, Organomation Associates, Inc. partnered with BioChromato to provide a vacuum-assisted Smart Evaporator to customers in North America.
  • In April 2018, Yamato Scientific opened its new R&D Center in Saitama Prefecture, Japan.
  • In May 2017, Organomation Associates enhanced its MICROVAP product line with the addition of four new product offerings.

The research & academic institutes end-user segment is expected to grow at a high CAGR

The solvent evaporation market, by the end-user, includes pharmaceutical & biopharmaceutical industry, diagnostic laboratories, and research & academic institutes. The research & academic institutes segment is expected to grow at the highest CAGR during the forecast period due to factors such as the increasing drug development studies and the rising demand for continuous innovation and enhancement of existing products.

Request for sample pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=68290365

Regional Growth Analysis:

The North American market accounted for the largest share of the solvent evaporators industry in 2018. This is attributed to the increase in life sciences R&D, rising focus on improving the safety & quality of healthcare, growing efforts to increase the output of the healthcare industry, growth in the biosimilars & generics market, rising demand for high-quality research tools for data reproducibility, and increasing focus on developing personalized therapeutics. The presence of a large number of global players in this region is another key factor contributing to the large share of this market segment.

Tensiometer Market worth USD 151 million : Need to Improve Product Quality and Manufacturing Processes

Expected Revenue Growth :

[131 Pages Report] The global tensiometer market is expected to reach USD 151 million by 2024 from an estimated value of USD 103 million in 2019, growing at a CAGR of 7.9% during the forecast period

What This Report Will Provide?

This study on the global tensiometer market involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Major Growth Boosters :

The global market for tensiometer is primarily driven by the need to improve product quality and manufacturing processes, increasing pharmaceutical and biopharmaceutical R&D expenditure, and technological advancements. However, the reluctance to switch from conventional methods and a dearth of skilled personnel will challenge market growth.

Download PDF Brochure :  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=10015314

The optical tensiometers segment is projected to grow at the highest CAGR during the forecast period

On the basis of product, the tensiometer market is segmented into optical tensiometers, force tensiometers, volumetric tensiometers, bubble pressure tensiometers, and accessories. The optical tensiometers segment accounted for the largest market share in 2018. The large share of this segment is mainly attributed to the large adoption of optical tensiometers in the chemical, oil & gas, energy, pharmaceutical, and material & coating industries in the R&D and quality control of products.

In 2018, the chemicals industry segment accounted for the largest share of the market

On the basis of industry, the tensiometer market is segmented into chemical, oil & gas, energy, pharmaceutical & biopharmaceutical, medical device, cosmetic, and other industries (food & beverage, materials & composite, textile, and paper & packaging industries). The chemical industry segment accounted for the largest share of the tensiometers market in 2018.

Request Sample Report : https://www.marketsandmarkets.com/requestsampleNew.asp?id=10015314

 

Regional Growth Analysis:

The market is segmented into five major regions, namely, North America, Europe, the Asia Pacific (APAC), Latin America, and the Middle East & Africa. In 2018, Asia Pacific accounted for the largest share of the tensiometer market. The factors such as chemical production growth in China, growth in Indian oil & gas industry, increasing demand for primary energy in India, and growth in medical device & pharmaceutical market in Asia are driving the growth of the tensiometer industry in this region.

Source: http://www.marketsandmarkets.com/Market-Reports/tensiometer-market-10015314.html

Cardiology Information System (CIS) Market : Favorable Government Initiatives

Growth in this market is mainly driven by the increasing incidence and prevalence of cardiovascular disease, government initiatives in China, and the increasing number of hospitals.

[54 Pages Report] The China cardiology information system market is projected to reach $54 million by 2024 from $35 million in 2019, at a CAGR of 8.9% during the forecast period.

The study involved four major activities in estimating the current market size of the China cardiology information system market. Exhaustive secondary research was conducted to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Then, both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.

Market Dynamics

  • Rising Incidence and Prevalence of Cardiovascular Disease in China
  • Increasing Number of Hospitals in China
  • Favorable Government Initiatives

Based on system, the market is segmented into integrated and standalone systems. The integrated systems segment is projected to witness the highest growth during the forecast period. The increasing adoption of integrated systems by healthcare providers is the major factor supporting the growth of this segment.

Download PDF Brochure @  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=264168583 

By component, the market is segmented into software, services, and hardware. The software segment accounted for the largest market share in 2018. The large share of this segment can be attributed to the growing need to integrate CVIS with C-PACS, EMRs, and other cardiology modules.

Based on end user, the market is segmented into L3A hospitals and L3B & L2 Hospitals. The L3A hospitals segment accounted for the largest share of the market in 2018. The increasing number of L3A hospitals in China and growing disease prevalence are responsible for the large share of this market segment.

Some key players mentioned in the research report are:

Key players in the China cardiology information system market are Philips Healthcare (Netherlands), CREALIFE Medical Technology (CHINA), Central Data Network (Australia), Infinitt Healthcare (South Korea) and Esaote (OTCPK:OTCPK:ITALY).

Request for sample pages @   https://www.marketsandmarkets.com/requestsampleNew.asp?id=264168583 

Source: http://www.marketsandmarkets.com/Market-Reports/cardiology-information-system-market-264168583.html

Intraoperative Radiation Therapy Market Reach USD 66 Million By 2025 : Technological Advancements in the field of Electron IORT

The rising incidence of cancer, technological advancements, and advantages offered by IORT over conventional radiotherapy are the major factors driving the growth of the global intraoperative radiation therapy market. Additionally, growing clinical trials exploring the use of IORT for various cancer applications is expected to offer lucrative growth opportunities to market players.

[159 Pages Report] The global intraoperative radiation therapy market is projected to reach USD 66 million by 2025 from USD 48 million in 2020, at a CAGR of 6.4% during the forecast period.

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, fundamental market dynamics, and key player strategies.

Market Dynamics

1. Growing global prevalence of cancer
2. Improving reimbursement scenario
3. Procedural advantages over EBRT
4. Technological advancements

COVID-19 Impact on the global Intraoperative radiation therapy market

The intraoperative radiation therapy market was significantly impacted by the COVID-19 pandemic. Various screening, diagnostic, and surgical procedures were restricted or postponed at hospitals and cancer treatment centers, which resulted in disruptions in the cancer diagnosis as well as treatment market. The pandemic also impacted the availability of healthcare resources. Major regulatory authorities across the globe, such as the CDC, WHO, MHRA, TGA, and EMA, have identified cancer patients at a greater risk of contracting coronavirus disease than healthy adults. In order to reduce the burden on the patient and staff while reducing the risk of exposure, few alternate dose-fractionation regimens were suggested by regulatory authorities.

Download PDF Brochure @  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=245000083 

The IORT procedure is associated with various advantages such as targeted radiation, limited treatment time, high precision and radiation control, and minimal radiation exposure of normal tissue. This is especially true for breast cancer, as this mode offers women a choice of breast-sparing treatment (lumpectomy). The increasing prevalence of breast cancer is, therefore, a key factor driving the market growth. The growing prevalence of cancer will increase the adoption of IORT procedures.

The geographical regions mapped in the report are:1. North America2. Europe3. Asia-Pacific4. Latin America5. Middle East & Africa

North America, comprising the US and Canada, accounted major share of the intraoperative radiation therapy market in 2019. The major factors driving market growth in this region are the easy availability and high adoption of IORT for cancer treatment, the rising incidence of cancer, and significant per capita annual healthcare expenditure in the US and Canada. Furthermore, associations such as the American Society for Radiation Oncology (ASTRO) have advocated the use of low-energy IORT, which has contributed to its increased adoption in North America..

Some key players mentioned in the research report are:

The major players in the Intraoperative radiation therapy market are ZEISS Group (Germany), iCAD, Inc. (US), Eckert & Ziegler (Germany), Elekta AB (Sweden), GMV Innovating Solutions (Spain), Sensus Healthcare, Inc. (US), IntraOp Medical, Inc. (US), Isoray, Inc. (US), Becton, Dickinson and Company (US), Sordina IORT Technologies (OTCPK:ITALY), Varian Medical Systems, Inc. (US), SeeDos Ltd. (UK), IsoAid LLC (US), Ariane Medical Systems Ltd. (UK), Panacea Medical Technologies Pvt. Ltd. (India), Salutaris Medical Devices (US), Brainlab AG (Germany), RaySearch Laboratories (Sweden), REMEDI Co., Ltd. (South Korea), Merit Medical Systems, Inc. (US), among others.

Request for sample pages @  https://www.marketsandmarkets.com/requestsampleNew.asp?id=245000083

Source: http://www.marketsandmarkets.com/Market-Reports/intraoperative-radiation-therapy-market-245000083.html

Cell Therapy Technologies Worth USD 5.6 Billion By 2025 : It Is Creating Real Change In The Biotechnology Industry

Cell Therapy Technologies Worth USD 5.6 Billion By 2025 : It Is Creating Real Change In The Biotechnology Industry

The emerging economies such as Australia and China are expected to provide a wide range of growth opportunities for players in the market which is driven by their large and growing populations as well as increase in the number of clinical trials and investments in the field of personalized medicine in these countries. [ 173 Pages Report] The cell therapy technologies market is projected to reach USD 5.6 billion by 2025 from USD 2.8 billion in 2020, at a CAGR of 14.4% from 2020 to 2025. COVID -19 Impact on the Cell Therapy Technologies Market The outbreak of COVID-19 is expected to have a minimal or negligible negative impact on the cell therapy technologies market. The rise in the incidences of COVID has led to an increase in the need for an efficient drug or vaccine for COVID, which could help in reducing the severity of the cases. Cell-based research is an essential step during the manufacturing of vaccines, which can help in the growth of the market. Market Dynamics Rising government investments in cell-based research Rising incidence of chronic and infectious diseases Large number of oncology-related cell therapy clinical trials Increasing GMP certifications for cell therapy production facilities Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=213334978 Precision medicine is an evolving approach for disease treatment and prevention, which takes into account individual variability in genes, environments, and lifestyles. Precision medicine involves the selection of drugs wholly tailored to a patient based on disease condition and history. Although this practice is expanding into all disease areas, oncology has seen the most progress. The geographical regions mapped in the report are: North America Europe Asia-Pacific RoW On the basis of region, the cell therapy technologies market is segmented into North America, Europe, Asia Pacific, and Rest of the World. In 2019, North America commanded the largest share of the cell therapy technologies market. The large share of this market segment can be attributed to the increasing incidence of CVD, increasing healthcare expenditure, growing disposable income, growing healthcare awareness, and the availability of technologically advanced devices in the region. Rising government investments in cell-based research The need for newer, better therapies for diseases such as cancer and CVD has resulted in an overall increase in research activity, as well as the availability of funding for cell-based research. In November 2019, the Australian government released a 10-year roadmap for stem cell research in Australia—The Stem Cell Therapies Mission. The initiative would provide USD 102 million (AU$150 million) under the Medical Research Future Fund (MRFF) to support stem cell research to deliver new therapies.

Filter Integrity Test Market Worth USD 79 Million by 2024 : Growth In The Biopharmaceutical Industry

Major Growth Drivers:

Factors such as increasing R&D spending, growth in the biopharmaceutical industry, and increasing purity requirements in the end-user market are driving the growth of the market.

Expected Revenue Growth:

[106 Pages Report] The filter integrity test market is projected to reach USD 79 million by 2024 from USD 59 million in 2018, at a CAGR of 5.0% during the forecast period.

The filter integrity test market comprises several stakeholders such as raw material suppliers, manufacturers of filter integrity test, and regulatory organizations in the supply chain. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The primary interviewees from the demand side include key opinion leaders in research laboratories, academic institutes, and pharmaceutical & biotechnology companies.

Browse in-depth TOC on “Filter Integrity Test Market

80 – Tables

27 – Figures

106 – Pages

Download PDF Brochure:  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=46873904

Pharmaceutical and biopharmaceutical companies are the largest and fastest-growing end users of the filter integrity test market.

Based on end user, the filter integrity test market is segmented into pharmaceutical and biopharmaceutical companies, CMOs, and other end users. In 2018, the pharmaceutical and biopharmaceutical companies segment accounted for the largest share of the market. This segment is also expected to witness the highest growth during the forecast period owing to the growing biopharmaceutical industry, significant growth in the biologics market, and stringent government guidelines for purity requirements in pharmaceutical and biotechnology manufacturing.

Regional Growth Analysis:

The market is divided into four major regions—North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2018, North America accounted for the largest share of the market, followed by Europe. The increasing demand for biopharmaceuticals and implementation of drug safety guidelines by the FDA are the major factors driving the growth of the filter integrity test industry in North America.

Request for sample pages :  https://www.marketsandmarkets.com/requestsampleNew.asp?id=46873904

Key Market Players

The major players in the filter integrity test market are Merck KGaA (Germany), Danaher Corporation/Pall Corporation (US), Sartorius (Germany), Donaldson Company (US), Parker Hannifin Corporation (US), Meissner Filtration Product (US), MDI Filtration Technologies (US), Thermo Fisher Scientific (US), Eaton Corporation (Ireland), and SH-Surway (NASDAQ:CHINA).

Genotyping Assay Market worth USD 31.9 billion : Growing uptake of the hybrid approach of sequencing

The major factors that are expected to be driving the genotyping assay market are technological advancements and the decreasing prices of DNA sequencing. The increasing incidence of genetic diseases and rising awareness of personalized medicine, growing importance of genotyping in drug development, and the increasing demand for bioinformatics solutions in data analysis are also expected to promote market growth in the coming years.

MarketsandMarkets forecasts the Genotyping Assay market to grow from USD 11.8 billion in 2018 to USD 31.9 billion by 2023, at a Compound Annual Growth Rate
CAGR) of 22.0% during the forecast period.

Market Dynamics

1. Low Prices of Reprocessed Medical Devices
2. Pressure to Reduce Volume of Regulated Medical Waste

The sequencing segment is expected to witness a faster growth rate in this market due to factors such as, the increasing application areas of DNA sequencing technologies, technological advancements, the availability of high-speed sequencing instruments, and the growing uptake of the hybrid approach of sequencing.

Download PDF Brochure @  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=249958595

The pharmaceutical and biopharmaceutical companies segment is expected to witness the highest growth during the forecast period. The increasing demand for pharmacogenomics in the drug discovery and development process and recommendations from the FDA to include genotyping and pharmacogenomics studies in the course of drug discovery have contributed to the growth of this market segment.

The geographical regions mapped in the report are:

1. North America
2. Europe
3. Asia-Pacific
4. Latin America
5. Middle East and Africa

North America is expected to hold the largest market size in the global genotyping market during the forecast period, followed by the European region. The increasing adoption of technologically advanced genotyping products, the high healthcare expenditure, presence of advanced healthcare infrastructure, highly developed healthcare systems in the US and Canada, large number of genotyping-based R&D projects, and the presence of a large number of leading genotyping manufacturers in the region, along with an increasing demand from pharmaceutical companies for genotyping products and rising investments by government bodies, are responsible for the large share of the North American genotyping market.

Some key players mentioned in the research report are:

Illumina (US), Thermo Fisher Scientific (US), QIAGEN (Netherlands), Agilent Technologies (US), Danaher Corporation (US), Roche Diagnostics (Switzerland), GE Healthcare (US), Fluidigm Corporation (US), PerkinElmer (US), Eurofins Scientific (Luxembourg), Bio-Rad Laboratories (US), Pacific Biosciences of California (US), GENEWIZ (US), and Integrated DNA Technologies (US).

Request for sample pages  @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=249958595

Source: http://www.marketsandmarkets.com/Market-Reports/genotyping-market-249958595.html

Compound Management Market : Size Estimation And Analysis Of Wide Range Of Growth Opportunities For Industry Players

[118 Pages Report] The Compound management market is projected to reach USD 424.5 million in 2023 from USD 215.3 million in 2018, at a CAGR of 14.5% during the forecast period.

The growth of the market can be attributed to increasing drug discovery activities, the growing biopharmaceutical industry, and the rising trend in outsourcing compound/sample management.

Market Dynamics

  • Increasing Drug Discovery Activity
  • Growth of the Biopharmaceutical Industry
  • Rising Outsourcing of Compound/Sample Management
  • Growth of the Biobanking Sector

“By sample type, the chemical compounds segment to account for the largest share during the forecast period.”

The rising drug discovery activity is leading to an increased demand for compounds, which is positively affecting market growth.

Download PDF Brochure @   https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=182172928  

The outsourcing services segment is projected to register the highest CAGR during the forecast period. This high growth is due to the shift in trend towards outsourcing compound management to third-party service providers. These companies are experts in compound management and provide various services to pharmaceuticals, biopharmaceuticals, and CROs with regard to their compound storage needs, and are reasonably priced.

The geographical regions mapped in the report are:1. North America2. Europe3. Asia-Pacific4. Latin America5. Middle East and Africa

The large share of North America is attributed to the presence of the large pharmaceutical and biopharma industry. As a result, several companies in North America are engaged in drug discovery activities, which require the maintenance of substantial chemical libraries. Moreover, to maintain the productivity of such innovative drugs and biologics, most of the leading pharma and biopharma companies have started building compound management facilities or contracting external service providers.

Some key players mentioned in the research report are:

Brooks Automation (US), Hamilton Company (US), TTP Group (US), Labcyte (US), Biosero (US)

Request for sample pages @  https://www.marketsandmarkets.com/requestsampleNew.asp?id=182172928  

Source: http://www.marketsandmarkets.com/Market-Reports/compound-management-market-182172928.html

Autoinjectors Market worth USD 104.9 billion : Indicates Impressive Growth Rate In Medical Devices Industry

Market growth Market growth is largely driven by the growing prevalence of targeted therapies, the rising incidence of anaphylaxis, rising preference for self-administration of drugs, usability advantages, the increasing number of regulatory approvals, the availability of generic versions of autoinjectors, favorable reimbursements and government support, and technological advancements. The patent expiry of biologics is also expected to provide growth opportunities for players in the market.

[180 Pages Report] The global autoinjectors market is projected to reach USD 104.9 billion by 2025 from USD 46.0 billion in 2020, at a CAGR of 17.9% from 2020 to 2025.

Market Dynamics

  • Growing prevalence of targeted therapies
  • Rising incidence of anaphylaxis
  • Increasing number of regulatory approvals
  • Availability of generic versions of autoinjectors
  • Favorable reimbursements and government support
  • Ease of use increasing the preference for self-administration

COVID-19 Impact on The Autoinjectors Market

The COVID-19 pandemic has resulted in a global healthcare crisis, causing a shift in healthcare delivery in most regions. Most non-essential procedures and in-hospital therapies were deferred in the first half of 2020 to prevent the spread of the infection and ease the toll on healthcare infrastructure. According to researchers at Indiana University, healthcare visits decreased by around 40% in the first six weeks of the pandemic in the US, from early March to mid-April.

Download PDF Brochure @  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173991724  

The current COVID-19 pandemic has resulted in the implementation of a fresh set of protocols that aim to reduce patient visits to hospitals and clinics in non-emergency conditions to prevent both the transmission of the virus as much as make sure healthcare institutions are not overwhelmed. In this situation, the preference for home-use autoinjectors has risen among patients suffering from chronic illnesses and allergies. This also protects vulnerable high-risk populations from exposure to the virus during hospital visits.

The geographical regions mapped in the report are:

1. North America
2. Europe
3. Asia-Pacific
4. Latin America
5. Middle East and Africa

Geographically, the autoinjectors market is segmented into North America, Europe, the Asia Pacific, Latin America, and Middle East & Africa. Growth in the Asia Pacific market is majorly driven by the large diabetes population and increasing healthcare expenditure which has drawn a number of major autoinjector device manufacturers to this region. These companies are increasing their presence in the Asia Pacific market through several approaches, such as establishing sales offices and partnering with local pharmaceutical companies

Request for sample pages @   https://www.marketsandmarkets.com/requestsampleNew.asp?id=173991724  

Source: http://www.marketsandmarkets.com/Market-Reports/autoinjector-market-173991724.html

Particle Therapy Market Worth USD 1,349 Million by 2023 : Indicates Impressive Growth Rate In Medical Devices Industry

According to the new market research report “ Particle Therapy Market by Type (Heavy Ion, Proton Therapy), Products (Cyclotron, Synchrotron, Synchrocyclotron), Services, System (Single-room, Multi-room), Cancer Type (Pediatric, Prostate, Breast), Application (Treatment, Research) – Forecast to 2023“, published by MarketsandMarkets™, global particle therapy market is projected to reach USD 1,349 million by 2023 from USD 865 million in 2018, at a CAGR of 9.3%.

Exhaustive secondary research was done to collect information on the market and its different subsegments. The study involved four major activities to estimate the current market size for particle therapy. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.

Major Growth Drivers:

Growth in the particle therapy market is primarily driven by factors such as the various advantages offered by particle therapy over photon therapy, growing global prevalence of cancer, increasing adoption of particle therapy in clinical trials, and the increasing number of particle therapy centers worldwide.

Expected Revenue Growth:

The particle therapy market is projected to grow from an estimated USD 865 million in 2018 to USD 1,349 million by 2023, at a CAGR of 9.3% during the forecast period.

Synchrotrons are used to accelerate both protons and heavy ions such as carbon and hydrogen. The growth of the synchrotrons segment is attributed to factors such as the increasing number of research activities as well as the increasing investments in the development of synchrotron facilities.

Download PDF Brochure:   https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=12809137 

The large share of the proton therapy segment can be attributed to factors such as the high degree of precision, shorter treatment time, and reduced side-effects associated with proton therapy as compared to conventional photon therapies using X-rays. Other factors such as the increasing research activities in the field of radiation oncology using proton therapy systems, rising number of proton therapy centers, and longer equipment lifespan of proton therapy (30 years or more) in comparison to photon therapy (10 years) are expected to support the growth of this market in the coming years.

Asia Pacific is expected to hold a significant share in the particle therapy market during the forecast period

The Asia Pacific is one of the major revenue generating regions in the particle therapy market. China and Japan are the major countries responsible for the high growth of this regional market owing to factors such as the increasing per capita income, improving healthcare infrastructure, and supportive government activities in these emerging countries. Furthermore, the increasing geriatric population, growing incidence of cancer, and rising acceptance of particle therapy procedures and devices are also driving the growth of this regional market.

Request for sample pages :  https://www.marketsandmarkets.com/requestsampleNew.asp?id=12809137 

Source: http://www.marketsandmarkets.com/Market-Reports/particle-therapy-market-12809137.html

Primary Cells Market : Ethical Concerns Regarding Research In Cell Biology

According to the new market research report According to the new market research report “Primary Cells Market by Origin (Human Primary Cells, Animal Primary Cells), Type (Hematopoietic, Dermatocytes, Gastrointestinal, Hepatocytes, Lung, Renal, Musculoskeletal, Heart), End User, Region – Global Forecast to 2025“, published by MarketsandMarkets™, global primary cells market is projected to reach USD 1,613 million by 2025 from USD 970 million in 2020, at a CAGR of 10.7%.

Browse and in-depth TOC on “Primary Cells Market”

108 – Tables
34 – Figures
179 – Pages

Download PDF Brochure:  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=32854960

Major Growth Drivers:

Market growth is driven by the rising prevalence of cancer, increasing cancer research, rising investments in regenerative medicine research, rising demand for monoclonal antibodies, and rapid growth in the biotechnology and biopharmaceutical industries.

Expected Revenue Growth:

[179 Pages Report] The global primary cells market is projected to reach USD 1,613 million by 2025 from USD 970 million in 2020, at a CAGR of 10.7%.

COVID-19 Impact on Global Primary Cells Market

COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan (CHINA) in December 2019, COVID-19 has moved from a regional crisis to a global pandemic in just a matter of a few weeks. With the World Health Organization (WHO) officially declaring the outbreak of COVID-19 a pandemic, a mix of established pharmaceutical and biopharmaceutical companies, as well as small startups, have stepped forward to develop treatments and vaccines that target the infection caused by the novel coronavirus.

Based on origin, the primary cells market is segmented into human and animal primary cells. The human primary cells segment accounted for the largest share in the primary cells market in 2019. The increasing adoption of human primary cells in developing novel cancer therapies and the rising funding for the R&D for cell therapies are the major factors driving the growth of this segment.

Request Sample Reporthttps://www.marketsandmarkets.com/requestsampleNew.asp?id=32854960

“North America is the largest regional market for primary cells”

The global primary cells market is segmented into four major regions, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2019, North America accounted for the largest share in the primary cells market. The growth in the North American primary cells market can be attributed to the increasing number of players launching new human primary cells for research, expansion of the pharmaceutical and biotechnology industries, growing focus on R&D, and increasing prevalence of cancer in the region.

 

Source: http://www.marketsandmarkets.com/Market-Reports/primary-cells-market-32854960.html